Nippon Shinyaku Co., Ltd. Stock

Equities

4516

JP3717600005

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-19 am EDT 5-day change 1st Jan Change
4,205 JPY -0.92% Intraday chart for Nippon Shinyaku Co., Ltd. -3.09% -15.83%
Sales 2024 * 149B 964M Sales 2025 * 153B 992M Capitalization 283B 1.83B
Net income 2024 * 27.38B 177M Net income 2025 * 27.63B 179M EV / Sales 2024 * 1.4 x
Net cash position 2024 * 74.3B 480M Net cash position 2025 * 92.49B 598M EV / Sales 2025 * 1.24 x
P/E ratio 2024 *
10.4 x
P/E ratio 2025 *
10.3 x
Employees 2,186
Yield 2024 *
2.96%
Yield 2025 *
3.18%
Free-Float 90.75%
More Fundamentals * Assessed data
Dynamic Chart
Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy MT
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100 CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate MT
Jefferies Adjusts Nippon Shinyaku’s Price Target to 6,900 Yen From 6,700 Yen, Keeps at Buy MT
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023 CI
Jefferies Adjusts Nippon Shinyaku's Price Target to 6,700 Yen From 7,700 Yen, Keeps at Buy MT
Jefferies Upgrades Nippon Shinyaku to Buy From Hold, Adjusts Price Target to 7,700 Yen From 6,400 Yen MT
Nippon Shinyaku Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Jefferies Adjusts Nippon Shinyaku's Price Target to 6,400 Yen From 7,300 Yen, Keeps at Hold MT
Capricor Therapeutics Signs Commercialization, Distribution Deal With Nippon Shinyaku in Japan MT
Capricor Therapeutics, Nippon Shinyaku Enter Marketing Deal for Duchenne Muscular Dystrophy Treatment in US MT
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of Cap-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S CI
Clinigen JV To Launch Viltepso Managed Access Program For Duchenne Muscular Dystrophy Patients MT
Clinigen Group plc Signs Agreement with Nippon Shinyaku CI
Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku CI
More news
1 day-0.92%
1 week-3.09%
Current month-5.93%
1 month-8.88%
3 months-17.57%
6 months-24.72%
Current year-15.83%
More quotes
1 week
4 182.00
Extreme 4182
4 340.00
1 month
4 182.00
Extreme 4182
4 685.00
Current year
4 182.00
Extreme 4182
5 330.00
1 year
4 182.00
Extreme 4182
6 784.00
3 years
4 182.00
Extreme 4182
9 840.00
5 years
4 182.00
Extreme 4182
10 360.00
10 years
1 786.00
Extreme 1786
10 360.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO - -
President 52 95-03-31
Chairman 71 76-03-31
Members of the board TitleAgeSince
Director/Board Member 67 -
Compliance Officer 63 84-03-31
Director/Board Member 59 17-05-31
More insiders
Date Price Change Volume
24-04-19 4,205 -0.92% 230,400
24-04-18 4,244 -0.96% 234,500
24-04-17 4,285 -1.18% 209,000
24-04-16 4,336 +1.31% 225,900
24-04-15 4,280 -1.36% 170,700

Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT

More quotes
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4,205 JPY
Average target price
6,371 JPY
Spread / Average Target
+51.52%
Consensus